Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin plus rifaximin for prevention of ACLF in decompensated cirrhosis
NL-OMON55488Phase 3Active, not recruiting
- Sponsor
- August Pi i Sunyer Biomedical Research Institute
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis comparing Simvastatin + rifaximin with Placebo + placebo (2 arms). Primary endpoint: Time to first acute-on-chronic liver failure. Started Jan 2019; status: active, not recruiting.
02
Drugs
simvastatinrifaximin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NL-OMON55488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55488.